Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 13/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 11/20 | 0.51 |
| ▸ | INCENP | Q9NQS7 | 11/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1053333 | 0.96 | AURKA (0.54) | AURKAAURKBINCENPMEN1KMT2A | |
| SCHEMBL12931315 | 0.90 | AURKA (0.47) | AURKAAURKBINCENPALDH1A1 | |
| SCHEMBL12931310 | 0.88 | AURKA (0.46) | AURKAAURKBINCENPMEN1KMT2A | |
| SCHEMBL12931314 | 0.87 | AURKA (0.54) | AURKAAURKBINCENPTSHR | |
| Trifluoroacetic Acid SCHEMBL1055761 | 0.87 | AURKA (0.53) | AURKAAURKBINCENP | |
| Trifluoroacetic Acid SCHEMBL1056832 | 0.86 | AURKA (0.64) | AURKAAURKBINCENP | |
| SCHEMBL1052439 | 0.82 | AURKA (0.54) | AURKAAURKBINCENP | |
| SCHEMBL16361728 | 0.81 | AURKA (0.48) | AURKAAURKBINCENP | |
| SCHEMBL1501453 | 0.79 | AURKA (0.79) | AURKAAURKBINCENP | |
| SCHEMBL1501456 | 0.79 | AURKA (0.79) | AURKAAURKBINCENP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254888-B1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | MSD KK (JP) | 2014-12-24 | — | — | EP | claimed |
| US-8519136-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2013-08-27 | — | — | US | claimed |
| US-20110003833-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-06 | — | — | US | claimed |
| EP-2254888-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-12-01 | — | — | EP | claimed |
| WO-2009104802-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-27 | — | — | WO | claimed |
| EP-2254888-B1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | MSD KK (JP) | 2014-12-24 | — | — | EP | disclosed |
| US-8519136-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-8519136-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-20110003833-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2254888-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009104802-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003833-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | AURKA 1/4885AURKB 3/4885INCENP 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.